Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atabecestat in asymptomatic amyloid-positive individuals at risk for Alzheimer's dementia
2015-000948-42Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Atabecestat with Placebo (2 arms). Primary endpoint: Change from baseline in Preclinical Alzheimer Cognitive Composite. Started Aug 2015; status: terminated.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2015-000948-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000948-42.